NCT04662905 Novel Treatment Delivery of ECAP-controlled Closed-loop SCS for Chronic Pain
| NCT ID | NCT04662905 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Saluda Medical Pty Ltd |
| Condition | Chronic Pain |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2020-12-15 |
| Primary Completion | 2027-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2020-12-15 with a primary completion date of 2027-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to test and evaluate novel treatment delivery of ECAP-controlled closed loop SCS through the incorporation of new software and/or hardware features for patients with the Evoke System.
Eligibility Criteria
Inclusion Criteria: * 1\. Subject has undergone trial implant or is planning to be implanted with the Evoke System within its approved indication. * 2\. Subject is willing and capable of giving informed consent and able to comply with study-related requirements. Exclusion Criteria: N/A
Contact & Investigator
Angela M Leitner
STUDY DIRECTOR
Saluda Medical Pty Ltd
Frequently Asked Questions
Who can join the NCT04662905 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Chronic Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04662905 currently recruiting?
Yes, NCT04662905 is actively recruiting participants. Contact the research team at angela.leitner@saludamedical.com for enrollment information.
Where is the NCT04662905 trial being conducted?
This trial is being conducted at Garran, Australia, Bella Vista, Australia, Broadmeadow, Australia, Charlestown, Australia and 11 additional locations.
Who is sponsoring the NCT04662905 clinical trial?
NCT04662905 is sponsored by Saluda Medical Pty Ltd. The principal investigator is Angela M Leitner at Saluda Medical Pty Ltd. The trial plans to enroll 200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.